In Metastatic Prostate Cancer, Radiographic PFS Associated with Survival
the Cancer Therapy Advisor take:
According to a new study published by the Journal of Clinical Oncology, researchers have found that radiographic progression-free survival (rPFS) was highly consistent and associated with overall survival in a randomized trial of abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC).
Because progression-free survival in mCRPC studies has been inconsistently defined and poorly associated with overall survival, researchers sought to study a reproducible quantitative definition of rPFS to test for an association with overall survival.
Researchers defined rPFS as "≥ two new lesions on an 8-week bone scan plus two additional lesions on a confirmatory scan, ≥ two new confirmed lesions on any scan ≥ 12 weeks after random assignment, and/or progression in nodes or viscera on cross-sectional imaging, or death."
Results showed hazard ratios of 0.49 (95% CI: 0.41 - 0.60; P <0.001) and 0.53 (95% CI: 0.45 - 0.62; P < 0.001). The Spearman's correlation coefficient between rPFS and overall survival was 0.72.
The findings suggest that rPFS should be further developed as an intermediate endpoint in trials studying patients with mCRPC.
Radiographic progression-free survival was highly associated with overall survival in metastatic castration-resistant prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Pembrolizumab May Be Effective for Previously Treated Hepatocellular Carcinoma
- Cabozantinib May Improve Survival Outcomes in Relapsed Hepatocellular Carcinoma
- PEGPH20 Plus mFOLFIRINOX Worsens OS Among Patients With Pancreatic Cancer
- Gemcitabine Plus S-1 May Be Non-inferior to Standard Therapy for Biliary Tract Cancer
- Renal Cell Carcinoma: Cost of Treatment May Negate Impact of Treatment Advances